ATARA Biotherapeutics (ATRA) Misses Q2 EPS by 2c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.68), $0.02 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $960 thousand versus the consensus estimate of $4.36 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Guggenheim Reiterates Buy Rating on StubHub Holdings (STUB)
• BofA Securities Downgrades SailPoint Technologies Holdings (SAIL) to Neutral